DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kwan, K. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kwan, K. C.

Vol. 25, Issue 12, 1329-1336, 1997

Oral Bioavailability and First-Pass Effects

K. C. Kwan

Merck Research Laboratories

Existing experimental strategies for the in vivo evaluation of factors affecting oral bioavailability have been reviewed. Based on concepts that have evolved, an integrated set of strategies emerges that appears capable of providing estimates of the individual contributions attributable to absorption, losses in the gut lumen, and first-pass elimination in the gut wall and the liver. The only assumptions are linear pharmacokinetics and constant clearance between treatments. These methods are also suitable for the assessment of metabolite bioavailability after drug administration and the quantitative determination of sites of biotransformation and metabolite formation in vivo.

Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
J. M. Fujitaki, E. E. Cable, B. R. Ito, B.-H. Zhang, J. Hou, C. Yang, D. A. Bullough, J. L. Ferrero, P. D. van Poelje, D. L. Linemeyer, et al.
Preclinical Pharmacokinetics of a HepDirect Prodrug of a Novel Phosphonate-Containing Thyroid Hormone Receptor Agonist
Drug Metab. Dispos., November 1, 2008; 36(11): 2393 - 2403.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. W. Ward, J. W. Proksch, M. A. Levy, and B. R. Smith
Development of an in Vivo Preclinical Screen Model to Estimate Absorption and Bioavailability of Xenobiotics
Drug Metab. Dispos., January 1, 2001; 29(1): 82 - 88.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
S. K. Balani, L. R. Kauffman, F. A. deLuna, and J. H. Lin
Nonlinear Pharmacokinetics of Efavirenz (DMP-266), a Potent HIV-1 Reverse Transcriptase Inhibitor, in Rats and Monkeys
Drug Metab. Dispos., January 1, 1999; 27(1): 41 - 45.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.